Scientists test 'Off-the-Shelf' cell therapy as potential lifeline for tough leukemias
NCT ID NCT07109518
Summary
This early-stage study is testing the safety and finding the right dose of a new type of CAR-T cell therapy for adults with advanced CD7-positive blood cancers, specifically acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL), that have come back or not responded to standard treatments. The therapy uses 'universal' donor cells, designed to be ready for multiple patients without custom manufacturing. The main goal is to see how much of the treatment patients can tolerate and to check for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.